Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate
Kathryn B. Anderson,Robert V. Gibbons,Robert R. Edelman,Kenneth H. Eckels,Robert Putnak,Bruce L. Innis,Bruce L. Innis,Wellington Sun,Wellington Sun +8 more
Reads0
Chats0
TLDR
Interference and facilitation occurred between serotypes in the live vaccine candidate evaluated, and analyses suggest that it may be possible to exploit facilitation to increase overall seroconversion.Abstract:
BACKGROUND Live, multivalent vaccines have historically exhibited interference in humans; live dengue virus (DENV) vaccines have proven no exception. METHODS To characterize interactions between DENV serotypes in a tetravalent live-attenuated virus vaccine candidate, we analyzed data from a factorial clinical trial in which all combinations of high- and low-dose DENV serotypes were combined in 16 live-attenuated tetravalent vaccine formulations (N = 64) and administered to flavivirus-naive adult volunteers. Regression models considered the outcomes of reactogenicity and seroconversion, controlling for all serotype doses simultaneously. Additionally, results were compared against earlier evaluations of the same viruses administered as monovalent formulations. RESULTS DENV-1 was immunologically dominant in both monovalent and tetravalent formulations. In tetravalent formulations, DENV-1 and DENV-2 antagonized each other, with a high dose of one decreasing seroconversion to the other. However, high-dose DENV-1 significantly increased seroconversion against 3 or more serotypes, increasing seroconversion to DENV-1, DENV-3, and DENV-4. The highest reactogenicity occurred when DENV-1 was at high dose and all others were low; reactogenicity decreased with the incorporation of other high-dose serotypes. CONCLUSIONS Interference and facilitation occurred between serotypes in the live vaccine candidate evaluated. These analyses suggest that it may be possible to exploit facilitation to increase overall seroconversion.read more
Citations
More filters
Journal ArticleDOI
Dengue Virus NS Proteins Inhibit RIG-I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant.
TL;DR: The findings demonstrate that NS2A and NS4B proteins from dengue virus serotypes 1, 2, and 4 are inhibitors of RIG-I/MDA5-directed interferon beta (IFN-β) induction and that they accomplish this by blocking TBK1 activation.
Journal ArticleDOI
A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
Anna P. Durbin,Beth D. Kirkpatrick,Kristen K. Pierce,Daniel Elwood,Catherine J. Larsson,Janet C. Lindow,Cecilia M. Tibery,Beulah P. Sabundayo,Donna Shaffer,Kawsar R. Talaat,Noreen A. Hynes,Noreen A. Hynes,Kimberli Wanionek,Marya P. Carmolli,Catherine J. Luke,Brian R. Murphy,Kanta Subbarao,Stephen S. Whitehead +17 more
TL;DR: TV003 induced a trivalent or greater antibody response in 90% of flavivirus-naive vaccinees and is a promising candidate for the prevention of dengue.
Journal ArticleDOI
Reduced risk of disease during postsecondary dengue virus infections.
Sandra Olkowski,Brett M. Forshey,Brett M. Forshey,Amy C. Morrison,Amy C. Morrison,Claudio Rocha,Stalin Vilcarromero,Eric S. Halsey,Tadeusz J. Kochel,Thomas W. Scott,Thomas W. Scott,Steven T. Stoddard,Steven T. Stoddard +12 more
TL;DR: Preexisting heterotypic antibodies markedly reduced but did not eliminate the risk of disease in this study population, which improves understanding of how preinfection history can be associated with dengue outcomes and DENV transmission dynamics.
Journal ArticleDOI
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Jorge E. Osorio,Iván D. Vélez,Cynthia A. Thomson,Liliana Lopez,Alejandra Jiménez,Aurelia Haller,Shawn Silengo,Jaclyn Scott,Karen L. Boroughs,Janae L. Stovall,Betty E. Luy,John Arguello,Mark E. Beatty,Joseph D. Santangelo,Gilad Gordon,Claire Y.-H. Huang,Dan T. Stinchcomb +16 more
TL;DR: The findings emphasise the acceptable tolerability and immunogenicity of the tetravalentDENVax formulations in healthy, flavivirus-naive adults and further clinical testing of DENVax in different age groups and in dengue-endemic areas is warranted.
Journal ArticleDOI
Identifying protective dengue vaccines: Guide to mastering an empirical process
TL;DR: It is suggested that preclinical testing adopt more rigorous criteria for protection and that Phase I testing be extended to require evidence of solid monotypic protective immunity for each component of a dengue vaccine by direct challenge with live-attenuated DENV.
References
More filters
Journal ArticleDOI
Dengue and Dengue Hemorrhagic Fever
TL;DR: A review of the changing epidemiology of dengue and hemorrhagic fever by geographic region, the natural history and transmission cycles, clinical diagnosis of both Dengue fever and DVF, serologic and virologic laboratory diagnoses, pathogenesis, surveillance, prevention, and control can be found in this paper.
Dengue and dengue hemorrhagic fever.
TL;DR: A major challenge for public health officials in all tropical areas of the world is to devleop and implement sustainable prevention and control programs that will reverse the trend of emergent dengue hemorrhagic fever.
Journal ArticleDOI
Research on dengue during World War II.
TL;DR: Dengue research was brought from the field into the laboratory and further progress has been made possible by work on experimental animals instead of on human volunteers, and a great deal more was learned about the basic properties of the dengue viruses.
Journal Article
A plaque reduction test for dengue virus neutralizing antibodies.
TL;DR: Experiments designed to test the accuracy of the antibody measurement are presented and analysed by the method for a parallel line graded response assay, and statistical analysis indicates a high degree of accuracy.
Journal ArticleDOI
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.
TL;DR: Although advances in molecular biology may ultimately lead to the development of more-immunogenic vaccine candidates, approaches such as increasing the number of doses of TOPV, mass vaccination campaigns, and combined use of oral and inactivated vaccines should also be considered.
Related Papers (5)
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
The global distribution and burden of dengue
Samir Bhatt,Peter W. Gething,Oliver J. Brady,Jane P. Messina,Andrew Farlow,Catherine L. Moyes,John M. Drake,John M. Drake,John S. Brownstein,Anne G. Hoen,Osman Sankoh,Osman Sankoh,Monica F. Myers,Dylan B. George,Thomas Jaenisch,G. R. William Wint,Cameron P. Simmons,Thomas W. Scott,Thomas W. Scott,Jeremy Farrar,Jeremy Farrar,Simon I. Hay,Simon I. Hay +22 more